

Efficacy of Bailing Capsule (Traditional Chinese Medicine) in the Treatment of Nephrotic Syndrome: A Meta-analysis

L. WANG*

Department of Gastroenterology, Medical Institute of Guizhou Medical University, Guizhou, PR China

Wang: Efficacy of Bailing Capsule in the Treatment of Nephrotic Syndrome

Meta-analysis of the existing literature on the treatment of nephrotic syndrome with Bailing capsule in adult patients was carried out to provide evidences for clinical practice. Relevant articles describing the effect were included. A total of 5 documents were selected. The meta-analysis showed that Bailing capsule reduced 24 h urine protein in patients with nephrotic syndrome (standardized mean difference=2.35 (3.72, 0.97), $p<0.01$), increased the level of serum albumin (standardized mean difference=0.94 (0.37, 1.52), $p=0.01$), but had no improvement on serum creatinine (standardized mean difference=0.50 (1.25, 0.26), $p=0.20$) as well as blood urea nitrogen (standardized mean difference=0.10 (0.36,0.17), $p=0.48$). The adjuvant treatment of nephrotic syndrome with Bailing capsule could reduce proteinuria, enhance plasma albumin and decrease blood lipids in patients. However, these conclusions need to be confirmed by further clinical trials.

Key words: Bailing capsule, nephrotic syndrome, proteinuria, urea nitrogen, meta-analysis

Clinical nephrotic syndrome (NS) is manifested as proteinuria, hypoalbuminemia and hyperlipidemia, which, in the long run, will promote glomerular sclerosis during the progress of NS and gradually develop into end-stage renal failure^[1]. In traditional Chinese medicine (TCM), NS belongs to the category of edema and essence and vital energy collapse. The disease is characterized by edema and TCM postulates that the pathological mechanism is mainly spleen and kidney dysfunction, deficiency of as well as *qi* and blood, especially the deficiency of *yang qi* is Ben and

water-dampness, damp and hot as well as stagnation of blood stasis is *Biao*, represented as both of deficiency and excess; and it is susceptible to exogenous evils during the course of the disease and the condition is likely to be aggravated due to infections caused by exogenous pathogenic factors^[2,3]. The pathogenesis of NS is complicated, closely related to lung, spleen and kidney. At present western medicine mainly uses glucocorticoids treatment and cytotoxic drugs, which pose many problems such as recurrence, hormone dependence and toxic side effects despite

*Address for correspondence

E-mail: tianshi8552853@163.com

certain beneficial effects^[4,5]. In recent years, adjuvant treatment of NS with Chinese medicines and Chinese medicinal preparations gradually has received much attention in clinic. Bailing capsules (dry powder of *Cordyceps sinensis* mycelia) have many effects, such as regulating the body's immune function^[6]. Protecting liver and kidney functions, stimulating hematopoiesis, improving hypoproteinemia and hyperlipidemia, reducing infection and lowering proteinuria^[7]. However, there has been little research into the application of Bailing capsules in patients after renal transplantation^[8]. Bailing capsule is a self-developed *Cordyceps sinensis* preparation in China and it has been reported by many studies to reduce proteinuria and improve renal function in patients with NS^[9]. In this paper, meta-analysis of articles that reported the treatment effect of Bailing capsule on adult patients with NS was performed so as to provide basis for clinical decision.

The inclusion criteria were, randomized controlled or controlled clinical trials with a single study of Bailing capsule, study subjects were adult patients with NS, articles published in Chinese or English, relative risk of Bailing capsule treatment and the confidence interval were reported in the article or could be calculated according to the reported data.

The primary index was 24 h urine protein followed by the levels of serum albumin, blood lipid, serum creatinine and blood urea nitrogen. The study quality was evaluated by Jadad score, including randomized trial methods, double-blind trial and the missing of research objects, the total score was 5 points and the point value over 4 suggested high qualities. The indices of effect size were assessed by standardized mean difference (SMD). Heterogeneity test was conducted using Q test and I^2 test, $p > 0.1$ and $I^2 \leq 50\%$ suggested that there was no significant heterogeneity and then the fixed effect model was adopted. Otherwise, it was considered that there was significant heterogeneity and then the random effect model was used for analysis. Funnel plot was drawn to analyze the publication bias.

The statistical analysis was conducted on Revman 5.0 software. In addition, the index without enough study subjects (< 3) was only given a descriptive evaluation.

A total of 68 articles were screened and 5 of them were finally included after removal of repeated publications, titles and abstracts as well as full text screening^[10-14]. All studies included were randomized controlled or controlled clinical trials carried out in China and published in Chinese. The study sample was obtained from a total of 417 persons, of which 189 were in the experimental group and 228 in the control group, as shown in Table 1. All trials failed to be of high quality.

The meta-analysis results showed that Bailing capsule can significantly reduce 24 h urinary protein in patients with NS (SMD=2.35 (3.72, 0.97), $p < 0.01$) and the sensitivity analysis demonstrated that with the elimination of references in research by a particular group, Bailing capsule still can significantly reduce 24 h urinary protein in patients (SMD=0.76 (1.41, 0.10), $p = 0.02$). Besides, Bailing capsule can improve the level of serum albumin (SMD=0.94 (0.37, 1.52), $p = 0.01$), but had no significant improvement in the levels of serum creatinine (SMD=0.50 (1.25, 0.26), $p = 0.20$) and blood urea nitrogen (SMD=0.10 (0.36, 0.17), $p = 0.48$), as shown in fig. 1. In addition, two studies (Zhong *et al.*^[11] and Chen^[14]) reported that Bailing capsule can reduce total cholesterol, triglyceride and low




Fig. 1: Urine protein

TABLE 1: RESEARCH FEATURES OF THE INCLUDED LITERATURE

Authors	Basic medicine	Bailing capsule dose	Subjects in experimental group/ subjects in control group	Treatment time
Wenqi Zhong	prednisone	1.0 g, tid	20/66	2 mo
Ying Liu	prednisone	5 tablets, tid	34/34	2 mo
Cheng Chen	hormone, corticosteroid	1.0 g, tid	40/45	3 mo
Hongmin Cao	enalapril	3 tablets, tid	48/48	6 mo
Sha Li	hormone	4 tablets, tid	42/40	3 mo

density lipoprotein (LDL) and one report showed that Bailing capsule can increase the level of high density lipoprotein (HDL, Tables 2-5).

Q heterogeneity test and I^2 test showed that except the effect size index of blood urea nitrogen ($p=0.86$, $I^2=0\%$), there was significant heterogeneity in the combination of other indicators. The funnel plot indicated a possibility of publication bias, as shown in fig. 2.

In summary a total of 5 documents were included in the meta-analysis, which showed that Bailing capsule reduced 24 h protein urine in patients with NS, increased the level of serum albumin, did not cause any improvement in serum creatinine and blood urea

nitrogen levels. However, 2 of the selected articles reported that Nailing capsules can reduce total blood cholesterol, triglycerides and LDL. These results suggested that the adjuvant treatment of NS with Bailing capsule can further reduce proteinuria, enhance plasma albumin and decrease blood lipids in patients, all of which, however, need to be confirmed by further clinical trials.

NS results from a variety of causes. If a large amount of urine protein is lost from the body, the content of plasma albumin would be reduced and then it will lead to the decrease of blood volume. The excretion of some fibrinogen or anticoagulant factors increases the viscosity of blood, giving rise to the disorders of

TABLE 2: EFFECT OF THE BAILING CAPSULE ON THE URINE PROTEIN IN PATIENTS

Study or subgroup	Bailing capsule group			Bailing capsule group			Weight	Std. Mean difference IV, Random, 95 % CI
	Mean	SD	Total	Mean	SD	Total		
Ying Liu	0.97	0.08	34	3.45	0.29	34	14.70 %	-11.53 [-13.58, -9.47]
Sha Li	0.9	0.42	42	0.91	0.041	40	21.40 %	-0.03 [0.47, 0.41]
Wenqi Zhong	3.1	0.97	20	3.83	1.33	66	21.20 %	-0.58 [-1.08, 0.07]
Cheng Chen	1.21	0.32	45	2.11	0.69	40	21.20 %	-1.69 [-2.19, -1.19]
Hongmi Cao	1.67	1.42	48	2.53	0.73	48	21.40 %	-0.76 [-1.16, -0.35]
Total (95 % CI)			189			228	100.00 %	-2.35 [-3.72, 0.97]

Heterogeneity: $Tau^2=2.26$; $Chi^2=129.61$; $df=4$ (<0.00001); $I^2=97\%$, test for overall effect: $Z=3.34$ ($p=0.0008$)

TABLE 3: ANALYSIS OF THE EFFECT OF BAILING CAPSULE ON SERUM CREATININE

Study or subgroup	Bailing capsule group			Control group			Weight	Std. mean difference IV, Random, 95 % CI
	Mean	SD	Total	Mean	SD	Total		
Ying Liu	34.16	5.47	34	29.48	3.58	34	32.60 %	1.00 [0.49, 1.51]
Wenqi Zhong	33.66	10.86	20	30.28	7.45	66	32.60 %	0.40 [-0.10, 0.91]
Hongmin Cao	35.72	3.21	50	28.51	6.51	50	34.8	1.39 [0.96, 1.83]
Total (95 % CI)			104			150	100.00 %	0.94 [0.37, 1.52]

Heterogeneity: $Tau^2=0.20$; $Chi^2=8.49$; $df=2$ ($=0.01$); $I^2=76\%$, test for overall effect: $Z=3.22$ ($p=0.001$)

TABLE 4: ANALYSIS OF THE EFFECT OF BAILING CAPSULE ON SERUM CREATININE

Study or subgroup	Bailing capsule group			Control group			Weight	Std. mean difference IV, Random, 95 % CI
	Mean	SD	Total	Mean	SD	Total		
Ying Liu	125.88	11.06	34	126.59	13.24	34	25.00 %	-0.06 [-0.53, 0.42]
Wenqi Zhong	43.48	11.75	20	71.5	15.56	66	23.80 %	-1.88 [-2.46, -1.30]
Cheng Chen	90.53	20.01	45	90.11	19.87	40	25.40 %	0.02 [-0.41, 0.45]
Sha Li	88.67	18.58	42	91.44	15.75	40	25.80 %	-0.16 [-0.55, 0.23]
Total (95 % CI)			141			180	100 %	-0.50 [-1.25, 0.26]

Heterogeneity: $Tau^2=0.53$; $Chi^2=32.22$; $df=3$ (<0.00001); $I^2=91\%$, test for overall effect: $Z=1.29$ ($p=0.20$)

TABLE 5: ANALYSIS OF THE BAILING CAPSULE AFFECTING BLOOD UREA NITROGEN

Study or subgroup	Bailing capsule group			Control group			Weight	Std. mean difference IV, Random, 95 % CI
	Mean	SD	Total	Mean	SD	Total		
Ying Liu	125.88	11.06	34	129.26	23.15	34	31.7 %	-0.18 [-0.06, 0.29]
Wenqi Zhong	6.1	1.2	20	6.25	1.31	66	28.7 %	-0.12 [-0.62, 0.38]
Cheng Chen	5.83	1.8	45	5.85	1.72	40	39.6 %	-0.01 [-0.44, 0.41]
Total (95 % C)			99			140	100.0 %	-0.10 [-0.36, 0.17]

Heterogeneity: $Tau^2=0.00$; $Chi^2=0.29$; $df=2$ ($=0.86$); $I^2=0\%$, test for overall effect: $Z=0.70$ ($p=0.48$)




Fig. 2: Funnel plot of the effect of Bailing capsule on proteinuria

anticoagulation, coagulation, and fibrinolysis systems in human body and ending up in hyperlipidemia, ultimately leading to the dysfunction of glomeruli with disordered structure^[11]. Studies have shown that^[12-13] proteinuria can cause damages to glomerular intrinsic cells such as mesangial cells and podocytes as well as to tubulointerstitium. Persistent proteinuria can lead to the progression of renal injury and the level of proteinuria is closely related to the development of chronic renal failure. Therefore, the reduction of proteinuria is an important target for the treatment of NS^[14]. The results of this study revealed that Bailing capsule can effectively reduce proteinuria in patients with NS with a mechanism probably related to inhibition of the formation of glomerular sub epithelial immune complex, lowering the loss of anionic charge in glomerular basement membrane and alleviating glomerular high filtration. Furthermore, it has been reported that^[15] Bailing capsule can inhibit the activation of aldose reductase, thus reducing the permeability of glomerular basement membrane and reducing urinary protein.

Patients with NS are also characterized by hyperlipidemia. The deposited lipid can stimulate the proliferation of glomerular mesangial cells, increase extracellular matrix synthesis, promote tubulointerstitial fibrosis and glomerular sclerosis and thus aggravate renal injury^[16-17]. Additionally, hyperlipidemia will exacerbate the risk of cardiovascular disease, so it is also an independent risk factor for the progression of NS^[18]. The 2 studies included in this paper showed that Bailing capsule can reduce total cholesterol, triglyceride and LDL with the mechanism may associated with reduced lipid peroxide as well as enhanced superoxide dismutase and lecithin cholesterol acyl transferase (LCAT) activity.

It was also revealed in this study that Bailing capsule can improve the level of serum albumin in patients,

which may be related to proteinuria reduction and that meanwhile Bailing capsule enables to promote protein synthesis with an adrenocorticoid like effect.

However it is necessary to draw attention to the following limitations of the study, such as there was obvious inter-study heterogeneity among the trials, differing in basic treatment program, drug dose and duration of therapy as well as patient's pathological type and clinical manifestations; there was publication bias; there was limited number of studies of low quality and the cited documents all were Chinese version; the long-term efficacy of Bailing capsule failed to be observed. To sum up, this analysis shows that Bailing capsule can effectively reduce proteinuria and increase plasma albumin and may reduce blood lipids in patients with NS. But these need to be confirmed by further large-scale trials of high quality.

Conflict of interest:

No conflict of interest between any of the authors.

REFERENCES

1. Musa AM, Asha HA, Veress B. Nephrotic syndrome in Sudanese patients with schistosomiasis mansoni infection. *Ann Trop Med Parasitol* 2016;74:615-8.
2. Giglio S, Provenzano A, Mazzinghi B, Becherucci F, Giunti L, Sansavini G, *et al.* Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. *J Am Soc Nephrol* 2015;26:230-6.
3. Kengne SW, Massella L, Diomedei FC, Gianviti A, Vivarelli M, Greco M, *et al.* Risk factors for cyclosporin a nephrotoxicity in children with steroid-dependant nephrotic syndrome. *Clin J Amer Soci Nephro* 2016;4:1409-16.
4. Gee HY, Zhang F, Ashraf S, Kohl S, Sadowski CE, Vega-Warner V, *et al.* KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. *J Clin Invest* 2015;125:2375-84.
5. Kaneko K, Tsuji S, Kimata T, Kitao T, Yamanouchi S, Kato S. Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes. *World J Pediatr* 2015;11:21-8.
6. Cheung JK, Li J, Cheung AW, Cheung AW, Zhu Y, Zheng KY, *et al.* Cordysinocan, a polysaccharide isolated from cultured Cordyceps, activates immune responses in cultured T-lymphocytes and macrophages: signaling cascade and induction of cytokines. *J Ethnopharmacol* 2009;124:61-8.
7. Zhang JS. Effect of bailing capsule to treat chronic nephritis proteinuria. *Chin J Mord Durg Appl* 2010;4:30-31.
8. Wang W, Zhang XN, Yin H, Li XB, Hu XP, Liu H, *et al.* Effects of bailing capsules for renal transplant recipients: a retrospective clinical study. *Chin Med J* 2013;126:1895-9.
9. Zhang J, Xie S. Meta-analysis of the efficacy of bailing capsules on primary nephrotic syndrome. *Chin J Mod Appl Pharm* 2013;30:907-10.
10. Zuo L. The impact of prednisone and Bailing capsule on hem rheology of patients with nephrotic syndrome. *Chin J Ethnomed Ethnopharm* 2009;18:64-5.

11. Zhong W, Yang LR, Ni N. The combination treatment of fluvastatin and Bailing capsule for primary nephrotic syndrome. *Anthol Med* 2005;24:671-2.
12. Cao H. Clinical study on therapy of bailing capsule for Nephrotic syndrome. *Mod Diagn Treat* 2013;24:791.
13. Sha L, Wang L. The clinical observation of corbrin capsule to treated primary nephrotic syndrome. *Guide Chin Med* 2017;15:26-8.
14. Chen C. The therapeutic effectiveness of atorvastatin and Bailing capsules in the treatment of nephrotic syndrome. *J Clin Nephrol* 2010;10:281-3.
15. Yadav UC, Ighani-Hosseiniabad F, Van Kuijk FJ, Srivastava SK, Ramana KV. Prevention of posterior capsular opacification through aldose reductase inhibition. *Invest Ophthalmol Vis Sci* 2009;50:752-9.
16. He L, Wu P, Tan L, Le B, Du W, Shen T, *et al*. Characteristics of lipid metabolism including serum Apo lipoprotein M levels in patients with primary nephrotic syndrome. *Lipids Health Dis* 2017;16:167.
17. Chang JF, Lin WN, Tsai CC. Resolution of Late Steroid-Responsive Nephrotic Syndrome in a Patient with Alport Syndrome Treated with Atorvastatin. *Open J Pediatr* 2015;5:12-6.
18. Kengne SW, Massella L, Diomedei FC, Gianviti A, Vivarelli M, Greco M, *et al*. Risk factors for cyclosporin a nephrotoxicity in children with steroid-dependent nephrotic syndrome. *Clin J Am Soc Nephrol* 2016;4:1409-16.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

This article was originally published in a special issue, "XXXXXX" Indian J Pharm Sci 2020;82(1)sp1 issue1;XX-XX